Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Reports Positive Top-Line Results from CRN04777 Phase 1 MAD Cohorts


Crinetics ($CRNX) reports results from CRN04777 Phase 1 MAD study that support potential to treat hyperinsulinism regardless of underlying genetic mutation

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results


Crinetics reported financial results and provided a business update, noting that key milestones were achieved, significant additional capital raised, and world-class talent added to the company from the bench to the board.

Crinetics Pharmaceuticals Appoints Chris Robillard as Chief Business Officer


Crinetics ($CRNX) appointed Chris Robillard to the role of chief business officer. Mr. Robillard is an expert in designing and implementing strategies to capitalize on growth opportunities for biopharmaceutical companies.

Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors


Crinetics ($CRNX) today announced the appointment of Caren Deardorf to the company’s board of directors. Ms. Deardorf previously led commercial efforts at Biogen for neurological diseases, including rare congenital disorders.